Adir Et Compagnie

Les Laboratoires Servier

Adir, S.a.r.l.

Les Laboratories Servier

Adir

Claude Guillonneau

Gilbert Regnier

Yves Charton

Pierre Lestage

Jean-Paul Vilaine

Brian Lockhart

Solo Goldstein

Alain Pierre

Ghanem Atassi

Jacques Duhault

Jean Lepagnol

Albert Lenaers

Christine Breugnot

Emile R Bisagni

Michel Lonchampt

Nicolas Guilbaud

Michelle Boulanger

Emmanuel Canet

Jacques DuHault

Stephane Leonce

Jean-Pierre Iliou

Francois Roman

Annie Kamoun

Florence Mahlberg

A compound selected from those of formula (I): wherein: Medicinal products containing the same which are useful in the treatment of conditions requiring a specific nicotinic ligand of &#x3b1;4&#x3b2;2 receptors.

Polysubstituted 1,1-pyridylaminocyclopropanamine compounds

Polysubstituted 1,1-pyridyloxycyclopropanamine compounds

A compound selected from those of formula (I):wherein:

1,1- and 1,2-disubstituted cyclopropane compounds

The compounds of formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and A are as defined in the description, their optical isomers and N-oxides, and pharmaceutically acceptable addition salts thereof with an acid or base, and the use thereof as anti-tumor agents.

Ellipticine compounds

A compound of formula (I): ##STR1## wherein Ra represents linear or branched (C.sub.1 -C.sub.8)alkylene,

1,2-dithiolane compounds

Compounds of the formula: ##STR1## in which R.sub.1, R.sub.2, A and B are as defined in the description, their optical isomers, N-oxides and addition salts with a phar-maceutically acceptable acid, and their use as anti-tumor agents.

Bis-pyrido�4,3-b!carbazole compounds

The compounds of formula: ##STR1## in which: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and A are as defined in the description, their optical isomers and N-oxides and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as anti-tumour agents.

New substituted 2,2-dimethyl-.omega.-phenoxyalkanoic acids and esters of formula: ##STR1## wherein: X, A, B, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the specification, The corresponding enantiomers and diastereoisomers, and the physiologically tolerable salts thereof with appropriate bases. The products of the invention may be used therapeutically.

Substituted 2,2-dimethyl-omega-phenoxyalkanoic acids and esters

The invention provides new compounds pertaining to the class of: aryl methoxy phenyl alkyl heterocyclic spiro compounds, enantiomers, diastereoisomers and physiologically-tolerable salts thereof. For example: 8-{2-�3-quinol-2-yl methoxy)phenyl!ethyl}-3,8-diaza-1-oxa-2-oxo spiro�4,5!decane is described. Medicinal products containing the same are useful in the treatment of any pathology involving modifications of leukotriene metabolism.

Heterocyclic spiro compounds

New substituted phenoxyisobutyric acids and esters that can be used as medicaments and correspond to the formula: ##STR1## wherein X, A, R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and Z are as defined in the description. Those compounds and their physiologically tolerable salts can be used therapeutically.

Substituted phenoxyisobutyric acids and esters

The compounds are 8-substituted 1-oxa-2-oxo-3,8-diazaspiro [4.5]decanes useful for the treatment of dyslipidaemiae, atherosclerosis and pathologies in which membrane lipid peroxidation plays an initiating and/or aggravating role. A compound disclosed is (R,S)-8-[3(3,5-di-tert.-butyl-4-hydroxyphenylthio)-2-hydroxypropyl]-1-oxa- 2oxo-3,8-diazaspiro [4.5]decane.

Spiro(4.5.)decane compounds

1,3,7-trimethyl-8-[3-(4-diethylaminocarbonyl-piperazino) propyl] xanthine and physiologically tolerable acid addition salts thereof may be used for the preparation of medicaments for the treatment of memory disorders, intellectual disorders of ageing, and Alzheimer's disease.

Pharmaceutical compositions and a method for the treatment of memory

New morpholine compounds of the formula: ##STR1## in which: X, bonded to the aromatic nucleus, represents halogen or trifluoromethyl and R' represents hydrogen, (C.sub.1 -C.sub.5)alkyl optionally including a double bond, or aralkyl; in racemic and enantiomeric forms, and physiologically tolerable acid addition salts theroef. These compounds and their physiologically tolerable salts can be used therapeutically especially in the treatment of ischaemic syndromes and cerebral ageing.

Morpholine compounds, compositions and use

Spiro (4,5) decane compounds of the formula: ##STR1## in which: X is methyl and

Growing community of inventors

Clamart, France

Claude Guillonneau